Short answer
Celldex Therapeutics, Inc. (CLDX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$76M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$76M
- −12.7% YoY · −2.8% QoQ
- EPS (diluted)
- −$0.95
- +5.9% YoY · −2.2% QoQ
Source: XBRL data from the Celldex Therapeutics, Inc. (CLDX) Q3 2026 10-Q on SEC EDGAR. USD.
Celldex Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY from $0
- Operating margin not meaningful, operating loss $82.3M vs $73.6M YoY
- Barzolvolimab strongest program, Phase 3 CSU complete response up to 54.0% at Week 24
- Cash, equivalents and marketable securities $650.3M; operating cash use $188.0M
- BLA submission anticipated in 2027; higher barzolvolimab development costs expected near term
Risk Factors
- No material changes identified in the provided Risk Factors section, which contains no substantive risk-factor disclosure
- Liquidity risk: $650.3 million in cash, equivalents and marketable securities against $188.0 million operating cash burn
- Financing risk: future $52.5 million milestone payment may require cash, stock or a combination
- Regulatory risk: barzolvolimab remains subject to potential clinical-trial failure or regulatory approval delays
- Marketable-securities risk: unrealized-loss positions increased to $576.5 million from $19.4 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celldex Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.